SCHEMBL5216455

SCHEMBL5216455

Cc1ccc(Br)cc1-n1cc(-c2nc3ccccc3o2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.42
KDM4E B2RXH2 5/20 0.42
MAPT P10636 5/20 0.42
RAB9A P51151 5/20 0.42
ALDH1A1 P00352 4/20 0.42
HPGD P15428 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 2/20 0.42
HCRTR1 O43613 2/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 2/20 0.42
CASP3 P42574 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
SENP6 Q9GZR1 2/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MET P08581 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217963 0.82 NPC1 (0.46) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5218794 0.81 NPC1 (0.48) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5217102 0.79 MAPT (0.47) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5218678 0.78 PTPN2 (0.46) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5215874 0.77 NPC1 (0.46) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5224725 0.77 NPC1 (0.47) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5215401 0.77 NPC1 (0.51) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5217080 0.75 NPC1 (0.45) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5219184 0.75 RAB9A (0.44) NPC1KDM4EMAPTRAB9AALDH1A1
SCHEMBL5217836 0.75 ALDH1A1 (0.50) NPC1KDM4EMAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885KDM4E 2688/4885MAPT 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.